Boston Scientific Corporation $BSX Shares Sold by Grassi Investment Management

Grassi Investment Management lessened its position in Boston Scientific Corporation (NYSE:BSX) by 0.9% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 38,250 shares of the medical equipment provider’s stock after selling 350 shares during the period. Grassi Investment Management’s holdings in Boston Scientific were worth $4,108,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Brighton Jones LLC lifted its position in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares during the period. Fermata Advisors LLC acquired a new stake in Boston Scientific in the first quarter valued at about $287,000. Breakwater Capital Group lifted its holdings in shares of Boston Scientific by 2.9% in the 1st quarter. Breakwater Capital Group now owns 7,887 shares of the medical equipment provider’s stock valued at $796,000 after buying an additional 221 shares during the period. Foster Group Inc. acquired a new stake in shares of Boston Scientific in the 1st quarter valued at approximately $287,000. Finally, Generali Investments Management Co LLC lifted its holdings in shares of Boston Scientific by 14.4% in the 1st quarter. Generali Investments Management Co LLC now owns 30,912 shares of the medical equipment provider’s stock valued at $3,118,000 after buying an additional 3,886 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $18,659,923.46. The trade was a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

BSX has been the subject of several recent analyst reports. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and raised their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Canaccord Genuity Group raised their target price on Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research note on Saturday, September 27th. Finally, Leerink Partnrs upgraded shares of Boston Scientific to a “strong-buy” rating in a research note on Monday, June 16th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $120.79.

Boston Scientific Trading Up 1.1%

NYSE:BSX opened at $97.30 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $144.17 billion, a PE ratio of 57.91, a price-to-earnings-growth ratio of 2.32 and a beta of 0.61. The stock has a fifty day simple moving average of $102.93 and a 200-day simple moving average of $102.05. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm’s quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.